Welcome to our dedicated page for Agios Pharmaceuticals news (Ticker: AGIO), a resource for investors and traders seeking the latest updates and insights on Agios Pharmaceuticals stock.
Agios Pharmaceuticals, Inc. (AGIO) is a biopharmaceutical company at the forefront of pioneering therapies for rare diseases, focusing on cellular metabolism and precision medicine. Based in Cambridge, Massachusetts, Agios is dedicated to discovering and developing breakthrough medications that target cancer, rare genetic metabolic disorders, and metabolic immuno-oncology. The company's core mission is to create transformative small-molecule medicines with a precision approach, enabling genetically or biomarker-defined patient populations to benefit from early proof-of-concept in clinical development.
Agios boasts a robust clinical pipeline, with significant advancements in its leading PK activator, mitapivat. Recent achievements include the Phase 3 ENERGIZE and ENERGIZE-T studies of mitapivat in thalassemia, demonstrating statistically significant results in reducing transfusion burdens in transfusion-dependent patients. The company is preparing for FDA submissions based on these promising outcomes, aiming to deliver the first oral treatment option for thalassemia patients.
Financially, Agios reported a net revenue of $8.2 million for the first quarter of 2024 from PYRUKYND® (mitapivat) sales, reflecting a 15% increase over the previous quarter. The company's strong cash position, with $714.3 million in cash, cash equivalents, and marketable securities as of March 31, 2024, ensures support for ongoing programs and potential pipeline expansion into 2026. Agios also anticipates a significant financial milestone with potential FDA approval of vorasidenib, expected to bring in $1.1 billion from upfront and milestone payments.
Agios' commitment to diversity and inclusion extends beyond its internal team to its clinical trials, aiming to build trust and support among diverse patient communities. The company’s strategic partnerships and collaborations further reinforce its mission to innovate and deliver life-changing therapies.
To stay updated on the latest developments and financial news about Agios Pharmaceuticals, visit their official website.
Agios Pharmaceuticals (Nasdaq: AGIO) has received FDA orphan drug designation for its novel pyruvate kinase activator tebapivat (AG-946) in the treatment of myelodysplastic syndromes (MDS). This designation supports the development of medicines for rare disorders affecting fewer than 200,000 people in the U.S. and offers incentives such as tax credits and potential market exclusivity.
Tebapivat aims to be the first oral therapy addressing anemia due to ineffective erythropoiesis in lower-risk MDS, which affects 75,000-80,000 patients in the U.S. and EU5. Agios has completed a Phase 2a study and is initiating a Phase 2b study of tebapivat in lower-risk MDS. The company's lead PK activator, mitapivat, has previously received FDA orphan drug designation for other rare blood disorders.
Agios Pharmaceuticals (Nasdaq: AGIO), a leader in cellular metabolism and PK activation therapies for rare diseases, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company is scheduled to present on Wednesday, September 18, 2024, at 10:20 a.m. ET.
Investors and interested parties can access a live webcast of the presentation through the 'Events & Presentations' section of Agios' website at www.agios.com. For those unable to attend the live event, a replay of the webcast will be available on the company's website for at least two weeks following the presentation, ensuring widespread access to the information shared during the conference.
Agios Pharmaceuticals (Nasdaq: AGIO) is set to receive $1.1 billion in milestone payments following the FDA approval of vorasidenib for Grade 2 astrocytoma or oligodendroglioma. This includes $905 million from Royalty Pharma and $200 million from Servier, expected in Q3 2024. The payments will increase Agios' pro-forma cash position to $1.7 billion as of June 30, 2024.
This strong financial position will enable Agios to prepare for potential PYRUKYND® (mitapivat) launches in thalassemia (2025) and sickle cell disease (2026), while driving pipeline progress. The approval marks the first for Grade 2 glioma in over 20 years, highlighting Agios' expertise in discovering novel therapies for high unmet needs.
Agios Pharmaceuticals (NASDAQ: AGIO) reported its Q2 2024 financial results and business highlights. Key points include:
1. Positive topline data from Phase 3 ENERGIZE-T study for thalassemia treatment.
2. $905 million purchase agreement with Royalty Pharma for vorasidenib royalty.
3. Results from Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency.
4. PYRUKYND® net revenue of $8.6 million in Q2, a 5% increase from Q1.
5. Cash position of $645.3 million as of June 30, 2024.
6. Net loss of $96.1 million for Q2 2024.
7. R&D expenses increased to $77.4 million, while SG&A expenses rose to $35.5 million.
8. Plans to file sNDA for mitapivat in thalassemia by year-end 2024.
Agios Pharmaceuticals (Nasdaq: AGIO) announced topline results from the Phase 3 ACTIVATE-KidsT study of mitapivat in children with PK deficiency who are regularly transfused. While the prespecified statistical criterion for the primary endpoint was not met, the results were clinically meaningful. 28.1% of patients in the mitapivat arm achieved the primary endpoint of transfusion reduction response, compared to 11.8% in the placebo arm. Secondary endpoints of transfusion-free response and normal hemoglobin response were only observed in the mitapivat arm. The safety profile was consistent with previous observations in adults. Agios has also completed enrollment for the ACTIVATE-Kids study in non-regularly transfused children, with topline data expected in 2025.
Agios Pharmaceuticals (Nasdaq: AGIO), a leader in cellular metabolism and PK activation therapies for rare diseases, has announced a conference call and live webcast scheduled for August 1, 2024, at 8:00 a.m. ET. The event will cover Agios' second quarter 2024 financial results and other business highlights. Investors and interested parties can access the live webcast under the 'Events & Presentations' section of Agios' website. A replay will be available for at least two weeks following the presentation.
Agios Pharmaceuticals presented positive results from its Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia at the European Hematology Association 2024 Hybrid Congress. The study met its primary endpoint, showing a statistically significant increase in hemoglobin response compared to placebo. Key secondary endpoints, including improvements in FACIT-Fatigue Score and hemoglobin concentration, also achieved statistical significance. The study demonstrated clinically meaningful improvements in health-related quality of life measures and patient-reported outcomes. Agios plans to file for regulatory approval of mitapivat by the end of 2024.
Agios Pharmaceuticals (Nasdaq: AGIO) will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 8:40 a.m. ET. The company, known for its leadership in cellular metabolism and PK activation therapies for rare diseases, will provide a live webcast of the presentation, accessible via the 'Events & Presentations' section of its website. The webcast replay will be available on the company's site for two weeks.
Agios announced that its Phase 3 ENERGIZE-T study of mitapivat in adults with transfusion-dependent alpha- or beta-thalassemia met its primary endpoint of transfusion reduction response. The study achieved statistical significance in all key secondary endpoints.
Mitapivat demonstrated a significant reduction in transfusion burden compared to placebo, with 30.4% of patients achieving a transfusion reduction response versus 12.6% in the placebo group. Additionally, 9.9% of patients in the mitapivat arm achieved transfusion independence compared to 1.1% in the placebo arm. The U.S. marketing application for mitapivat will be submitted by the end of 2024.
Agios Pharmaceuticals (Nasdaq: AGIO) will present at the Goldman Sachs 45th Annual Global Healthcare Conference on June 10, 2024, at 1:20 p.m. ET. The company, known for its work in cellular metabolism and PK activation for rare diseases, will have its presentation webcast live on its website. The replay of this webcast will be available for at least two weeks post-event.
FAQ
What is the current stock price of Agios Pharmaceuticals (AGIO)?
What is the market cap of Agios Pharmaceuticals (AGIO)?
What does Agios Pharmaceuticals specialize in?
What are some recent achievements of Agios Pharmaceuticals?
What is the financial status of Agios Pharmaceuticals?
What is mitapivat?
What is the significance of the ENERGIZE-T study results?
How does Agios support diversity in clinical trials?
What are some key upcoming milestones for Agios in 2024?
What strategic partnerships does Agios have?
What is Agios' approach to ESG?
How can I stay updated on Agios Pharmaceuticals?
